Please login to the form below

Confidential contracting – the road to flexible pricing

Excellent clinical and financial value are drivers for success in pharma, but without efficient, targeted pricing and adequate confidential contracting schemes, the success of any product is not ensured.

A post on drug pricing by Joseph Jimenez, then CEO of Novartis, attracted a lot of attention in 2016. Jimenez stated:

“We believe in the efficacy of our products, and by collaborating with payers on solutions for reimbursement, we hope to help start a shift toward value pricing in the healthcare system. We want to be rewarded for the tangible outcomes our products provide patients, not for simply selling pills.”

While this concept is clear, it brings a number of uncertainties for both payers and industry:

  • How will the product perform in the real world?
  • What will be the real cost of the product?
  • What value-added activities can improve product performance dramatically?

Most of these uncertainties can be handled with three types of contract between payer and company, namely performance-based, finance-based, and value-added. However, in order to have any chance for success, contracting options must arrive at win-win agreements that meet the interests of decision-makers on both sides. Ideal contracting options will address a specific payer concern, create/use a competitive advantage, and, of course, fall within legal/regulatory boundaries.

Targeting specific payer concerns

Confidential discounts and rebates are frequently used to drive volume among price-sensitive payers. Payers like this type of contract, as they are easy to implement. Companies tolerate these contracts as they offer the opportunity to differentiate prices between customers without exposure; there is no risk for international reference pricing as these are based upon official list prices. However, discounts/rebates are not efficient for building a competitive advantage because they can be easily copied. Nevertheless, deep discounts on large volume products may create a hurdle for new entrants. Most US payers will not spend time in contracting discussions for products where they anticipate low utilisation.

Payer interest is not limited to low pricing, value for money, or per-patient cost, but also includes more specific concerns. Many private insurance firms are focused on growing and retaining their membership through patient support and formulary inclusion of innovative and effective medicines. Medco Health Solutions Inc. (now part of Express Scripts), for example, entered a partnership with Pfizer in 2011 to identify consumer subgroups and determine which products are most effective in each subgroup, therefore improving personalised care.5 The partnership has initiated precision medicine studies that comply with the Health Insurance Portability and Accountability Act of 1996 (HIPAA). It has also led to the creation of Pfizer Link, an online community for clinical trial participants from completed Pfizer-sponsored studies.

For some products, payers are highly interested in avoiding misuse, which can be costly and a potential legal problem. The use of growth hormones (GH) among adolescents is concerning, particularly if the patient is an athlete or has a bodybuilder relative who could abuse access to the drug.8 Merck Serono’s Easypod®, an electromechanical injection device that delivers the GH deficiency drug Saizen (somatropin), captures each instance of product utilisation. This allows contracts that offer rebates for any tracked instance of misuse or other reasons for non-adherence.9 Using this opportunity, Merck Serono convinced some European clients to drop GH tendering for such contracts.

To read the rest of the article, please visit:

2nd October 2019



Company Details

Valid Insight

+44 (0) 20 3750 9833

Contact Website

152-160 City Road
Kemp House
United Kingdom

Latest content on this profile

Webinar: How to develop an optimal value story for your product
This webinar is part of the ongoing expert insights series run by Valid Insight
Valid Insight
Last chance to register - Webinar: How to price a pharmaceutical product during a global economic recession
How can you ensure your product achieves optimal market access during a global economic recession?
Valid Insight
Are biobetters a market access opportunity?
Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen.
Valid Insight
Why are new medicinal products denied reimbursement in France?
Many medicinal products looking to launch are rejected for reimbursement in France. A manufacturer must convince the Transparency Committee that their product is safe, effective and offers added value relative to alternative treatments for successful market access. In this blog, we summarise the reasons for negative reimbursement decisions in 2017 and discuss common pitfalls manufacturers should avoid.
Valid Insight
Using TRAVELLESS™ to provide tailored pharmaceutical training
In May 2020, Valid Insight were scheduled to travel to Grenoble to deliver the market access modules as part of the Advanced Master’s in Biotechnology & Pharmaceutical Management programme with Grenoble Ecole de Management, a French graduate business school. The course has participants from varied backgrounds, but all from roles within the pharmaceutical industry.
Valid Insight
The vicious circle of pharmaceutical tendering
Pharmaceutical tendering and contracting has long been common in healthcare for medical devices and diagnostics; the Gulf Cooperation Council and the Jamaica Commodity Trading Company have been using pharmaceutical tendering since the 1970s. In the 1990s, international institutions such as the World Health Organisation and the World Bank endorsed tendering as the preferred procurement process for drugs.
Valid Insight